Clinical application of combined detection of serum tumor markers in the diagnosis of colorectal cancer
血清肿瘤标志物联合检验诊断结直肠癌的临床应用研究

摘要

目的 分析血清肿瘤标志物联合检测对结直肠癌的诊断价值。方法 选取2021年9月至2022年8月收治的结直肠癌患者25例为观察组，结直肠良性病变25例为对照组1，且同期健康体检者20例为对照组2。比较不同组别血清肿瘤标志物表现，不同临床分期结直肠癌患者肿瘤标志物的水平差异。结果 观察组的血清肿瘤标志物指数均较对照组1、2高，且CA724、CA199存在较大差异（P<0.05）。对直肠癌肿瘤标志物水平检测，CA724、CA199、CEA指数在病情分期延后时出现升高趋势，并且在临床观察中某些人群T4期没有升高趋势（P<0.05）。T4期和T3期的CA50、CA242指标存在差异较小，但是较T1~T2期相比存在明显上升空间（P<0.05）。结论 临床在对结直肠癌患者诊断时利用血清肿瘤标志物联合检验可准确的判定阳性，明确肿瘤标志物不同的分期表现，其检验结果和预后具有相关性。

Abstract

Objective To analyze the diagnostic value of combined detection of serum tumor markers for colorectal cancer.
Methods: From September 2021 to August 2022, 25 patients with colorectal cancer were selected as the observation group, 25 patients with benign colorectal lesions as the control group 1, and 20 healthy people as the control group 2. To compare the serum tumor markers in different groups and the difference of tumor markers in different clinical stages of colorectal cancer patients.
Results: The serum tumor marker indexes of the observation group were higher than those of the control groups 1 and 2, and there were significant differences in CA724 and CA199 (P<0.05). In the detection of tumor markers of rectal cancer, the indexes of CA724, CA199 and CEA showed an increasing trend when the disease stages were delayed, and in clinical observation, some people had no increasing trend in T4 stage (P<0.05). There is little difference in CA50 and CA242 indexes between T4 and T3, but there is obvious room for increase compared with T1-T2 (P<0.05).
Conclusion  : In clinical diagnosis of colorectal cancer patients, the combined test of serum tumor markers can accurately determine the positive, and clarify the different stages of tumor markers. The test results are related to the prognosis.